Problem and Opportunity – Intravascular and Urinary Catheters

​

Two of the most commonly utilized medical devices in hospitals, intravascular and urological catheters, are both plagued with infection, and in the case of vascular catheters, thrombotic complications. These complications lead to substantial risk to the patients and cost to the health care system. The average cost to treat a patient with a central line associated bloodstream infection is roughly $50,000. This is an annual multi-billion-dollar burden for the healthcare system, which is not fully reimbursed by Medicare.

​

Nytricx is developing a dual pronged technology that mimics natural antimicrobial and antithrombotic properties of NO and incorporates its activity for prolonged periods both infection and thrombosis. Nitric Oxide (NO) is a gas, produced continuously by the inner lining of healthy human blood vessels, to combat blood infections and thrombosis, as part of the body’s innate immune system. Nytricx has developed novel technology that incorporates the natural antimicrobial and antithrombotic properties of NO, and establishes this activity for prolonged periods. 

​